AMG 337

Drug Profile

AMG 337

Alternative Names: AMG-337

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Amgen
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 01 Dec 2016 Amgen completes a phase I trial in Solid tumours (Late-stage disease) in USA (PO) (NCT01253707)
  • 09 Nov 2016 Amgen terminates a phase II trial for Gastric cancer, Oesophageal cancer and other Solid tumours in USA, Canada, Chile, Peru, Australia, South Korea, United Kingdom, Austria, Belgium, Czech Republic, France, Greece, Germany, Hungary, Italy, Poland, Spain and Russia (NCT02016534)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top